SciStem Therapeutics

Industry: Regenerative medicine for bone fractures

SciStem is developing off-the-shelf cellular therapies to heal bones in humans and animals. The first-in-field therapies are designed to treat factures and bone defects that won’t heal on their own.
The company’s first product, Bone Putty, contains tissue-derived stem cells that are engineered to express a protein called bone morphogenetic protein. BMP helps the body produce bone faster. The product is intended for use in both people and dogs, and it can be administered by a doctor or veterinarian at the point of care.
SciStem’s Bone Putty has an estimated market opportunity of $2 billion for segmental bone defects and $2 billion for spinal fusions and craniofacial fractures.


Back to companies